Literature DB >> 6814340

Chlorpropamide and glibenclamide serum concentrations in hospitalized patients.

R Huupponen, J Viikari, H Saarimaa.   

Abstract

The relationships between the daily doses of the drugs and the steady state serum concentration was studied in 51 patients on chlorpropamide and in 27 patients on glibenclamide. All the patients were hospitalized during the study. A wide interindividual variation in chlorpropamide levels was observed and thus, the prediction of drug concentration was difficult from the dosage alone, despite a statistically significant correlation between the dose per body weight and the serum drug level. The differences could not be explained on the serum creatinine levels, age, sex, liver diseases or other drugs used concomitantly. In the case of glibenclamide, a wide interindividual variation in serum concentration of the drug also occurred.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814340

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  9 in total

1.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.

Authors:  J Kallio; R Huupponen; K Pyykkö
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 3.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Contributions of human cytochrome P450 enzymes to glyburide metabolism.

Authors:  Lin Zhou; Suresh B Naraharisetti; Li Liu; Honggang Wang; Yvonne S Lin; Nina Isoherranen; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Journal:  Biopharm Drug Dispos       Date:  2010-05       Impact factor: 1.627

5.  Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination.

Authors:  P J Neuvonen; S Kärkkäinen; R Lehtovaara
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

7.  Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors:  Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

8.  Roles of chlorpropamide, alcohol and acetaldehyde in determining the chlorpropamide-alcohol flush.

Authors:  L Groop; C J Eriksson; R Huupponen; R Ylikahri; R Pelkonen
Journal:  Diabetologia       Date:  1984-01       Impact factor: 10.122

9.  CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.

Authors:  Wotan Zeng; Yali Guo; Peixian Chen; Zhike Liu; Dafang Chen; Chunji Han
Journal:  J Diabetes Investig       Date:  2016-03-08       Impact factor: 4.232

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.